


Build your own complimentary poster for the office!



Supplement your Course Learning. It's fast and easy.



We'll ship it to you directly free of charge



The Evolving Landscape of Atopic Dermatitis During the
COVID-19 Pandemic:
A FOCUS ON JAK INHIBITORS

Please visit

<http://atopicderm.posterprogram.com/>

Atopic Dermatitis Overview

Resource	Address
Akuete K, Guffey D, Israelsen RB, et al. Multicenter prevalence of anaphylaxis in clinic-based oral food challenges. <i>Ann Allergy Asthma Immunol.</i> 2017;119:339-348.e1.	https://www.annallergy.org/article/S1081-1206(17)30595-1/fulltext
Bird JA, Crain M, Varshney P. Food allergen panel testing often results in misdiagnosis of food allergy. <i>J Pediatr.</i> 2015;166:97-100.e1	https://www.jpeds.com/article/S0022-3476(14)00718-5/fulltext
Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. <i>Br J Dermatol.</i> 2017;177:1316-1321.	https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.15641
Costa-Carvalho BT, Grumach AS, Franco JL, et al. Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice. <i>J Clin Immunol.</i> 2014;34:10-22.	https://link.springer.com/article/10.1007/s10875-013-9954-6
De Benedetto A, Agnihotri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis: A disease caused by innate immune defects? <i>J Invest Dermatol.</i> 2009;129:14-30.	https://www.jidonline.org/article/S0022-202X(15)34047-1/fulltext
Eyerich K, Eyerich S, Biedermann T. The multi-modal immune pathogenesis of atopic eczema. <i>Trends Immunol.</i> 2015;36:788-801.	https://www.cell.com/trends/immunology/fulltext/S1471-4906(15)00251-3
Fallon PG, Sasaki T, Sandilands A, et al. A homozygous frameshift mutation in the mouse <i>Flg</i> gene facilitates enhanced percutaneous allergen priming. <i>Nat Genet.</i> 2009;41:602-608	https://www.nature.com/articles/ng.358
Frischmeyer-Guerrero PA, Rasooly M, Gu W, et al. IgE testing can predict food allergy status in patients with moderate to severe atopic dermatitis. <i>Ann Allergy Asthma Immunol.</i> 2019;122:393-400.e2.	https://www.annallergy.org/article/S1081-1206(19)30001-8/fulltext
Gaudinski MR, Milner JD. Atopic dermatitis and allergic urticaria: Cutaneous manifestations of immunodeficiency. <i>Immunol Allergy Clin North Am.</i> 2017;37:1-10.	https://www.sciencedirect.com/science/article/abs/pii/S0889856116300790
Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. <i>Exp Dermatol.</i> 2018;27:409-417.	https://onlinelibrary.wiley.com/doi/full/10.1111/exd.13336
Hopp RJ. Eosinophilic esophagitis in pediatrics: The worst of all possible allergy worlds? <i>J Allergy (Cairo).</i> 2012;2012:179658.	https://www.hindawi.com/journals/ja/2012/179658/
Kabashima K. New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity. <i>J Dermatol Sci.</i> 2013;70:3-11.	https://www.jdsjournal.com/article/S0923-1811(13)00055-8/fulltext
Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. <i>Expert Rev Clin Immunol.</i> 2017;13:15-26.	https://www.tandfonline.com/doi/full/10.1080/1744666X.2016.1212660
Katelaris CH, Peake JE. 5: Allergy and the skin: Eczema and chronic urticaria. <i>Med J Aust.</i> 2006;185:517-522.	https://onlinelibrary.wiley.com/doi/abs/10.5694/j.1326-5377.2006.tb00670.x

Kim K. Influences of environmental chemicals on atopic dermatitis. <i>Toxicol Res.</i> 2015;31:89-96.	http://koreascience.or.kr/article/JAKO201520448048501.page
Lewis-Jones S. Quality of life and childhood atopic dermatitis: The misery of living with childhood eczema. <i>Int J Clin Pract.</i> 2006;60:984-992.	https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1742-1241.2006.01047.x
Manea I, Ailenei E, Deleanu D. Overview of food allergy diagnosis. <i>Clujul Med.</i> 2016;89:5-10.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777468/
Margolis DJ, Apter AJ, Gupta J, et al. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. <i>J Allergy Clin Immunol.</i> 2012;130:912-917.	https://www.jacionline.org/article/S0091-6749(12)01115-3/fulltext
McLean WHI. Filaggrin failure - From ichthyosis vulgaris to atopic eczema and beyond. <i>Br J Dermatol.</i> 2016;175(suppl 2):4-7.	https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.14997
Napolitano M, Megna M, Patruno C, Gisondi P, Ayala F, Balato N. Adult atopic dermatitis: A review. <i>G Ital Dermatol Venereol.</i> 2016;151:403-411.	https://www.minervamedica.it/en/journals/dermatologia-venereologia/article.php?cod=R23Y2016N04A0403
Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. <i>J Allergy Clin Immunol.</i> 2003;112:252-262.	https://www.jacionline.org/article/S0091-6749(03)01461-1/fulltext
Owen JL, Vakharia PP, Silverberg JI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. <i>Am J Clin Dermatol.</i> 2018;19:293-302.	https://link.springer.com/article/10.1007/s40257-017-0340-7
Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis. <i>J Allergy Clin Immunol.</i> 2019;143:26-35.	https://www.jacionline.org/article/S0091-6749(18)31664-6/fulltext
Palmer CNA, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. <i>Nat Genet.</i> 2006;38:441-446.	https://www.nature.com/articles/ng1767
Paternoster L, Standl M, Waage J, et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. <i>Nat Genet.</i> 2015;47:1449-1456.	https://www.nature.com/articles/ng.3424
Sanna L, Stuart AL, Pasco JA, et al. Atopic disorders and depression: Findings from a large, population-based study. <i>J Affect Disord.</i> 2014;155:261-265.	https://www.sciencedirect.com/science/article/abs/pii/S0165032713008070
Schmitt J, Buske-Kirschbaum A, Tesch F, et al. Increased attention-deficit/hyperactivity symptoms in atopic dermatitis are associated with history of antihistamine use. <i>Allergy.</i> 2018;73:615-626.	https://onlinelibrary.wiley.com/doi/abs/10.1111/all.13326
Siegfried EC, Hebert AA. Diagnosis of atopic dermatitis: Mimics, overlaps, and complications. <i>J Clin Med.</i> 2015;4:884-917.	https://www.mdpi.com/2077-0383/4/5/884
Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population-based study. <i>J Allergy Clin Immunol.</i> 2013;132:1132-1138.	https://www.jacionline.org/article/S0091-6749(13)01366-3/fulltext
Silverberg NB. A practical overview of pediatric atopic dermatitis, part 3: Differential diagnosis, comorbidities, and measurement of disease burden. <i>Cutis.</i> 2016;97:408-412.	https://pubmed.ncbi.nlm.nih.gov/27416084/
Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and	https://www.annallergy.org/article/S1081-1206(18)30628-8/fulltext

cardiovascular comorbidities in US adults. <i>Ann Allergy Asthma Immunol.</i> 2018;121:604-612.e3.	
Silverberg JI. Revolutionizing atopic dermatitis. <i>Cutis.</i> 2019;104:142-143.	https://www.mdedge.com/dermatology/article/207466/atopic-dermatitis/revolutionizing-atopic-dermatitis
Tamari M, Hirota T. Genome-wide association studies of atopic dermatitis. <i>J Dermatol.</i> 2014;41:213-220.	https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.12321
Thijs JL, de Bruin-Weller MS, Hijnen D. Current and future biomarkers in atopic dermatitis. <i>Immunol Allergy Clin North Am.</i> 2017;37:51-61.	https://www.sciencedirect.com/science/article/abs/pii/S0889856116300716
Whiteley J, Emir B, Seitzman R, Makinson G. The Burden of atopic dermatitis in US adults: Results from the 2013 National Health and Wellness Survey. <i>Curr Med Res Opin.</i> 2016;32:1645-1651.	https://www.tandfonline.com/doi/full/10.1080/03007995.2016.1195733
Yaghamaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. <i>J Allergy Clin Immunol.</i> 2013;131:428-433.	https://www.jacionline.org/article/S0091-6749(12)01762-9/fulltext

Treatment of Atopic Dermatitis

Resource	Address
Agusti-Mejias A, Messeguer F, García R, Febrer I. Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. <i>Ann Dermatol.</i> 2013;25:368-370.	https://anndermatol.org/DOIx.php?id=10.5021/ad.2013.25.3.368
Arkwright PD, Motala C, Subramanian H, et al. Management of difficult-to-treat atopic dermatitis. <i>J Allergy Clin Immunol Pract.</i> 2013;1:142-151.	https://www.sciencedirect.com/science/article/abs/pii/S221321981200013X
Bass AM, Anderson KL, Feldman SR. Interventions to increase treatment adherence in pediatric atopic dermatitis: A systematic review. <i>J Clin Med.</i> 2015;4:231-242.	https://www.mdpi.com/2077-0383/4/2/231
Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. <i>Clin Exp Dermatol.</i> 2003;28:549-553.	https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2230.2003.01357.x
Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. <i>N Engl J Med.</i> 2021;384:1101-1112.	https://www.nejm.org/doi/10.1056/NEJMoa2019380
Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: A phase IIa randomized trial. <i>Br J Dermatol.</i> 2016;175:902-911.	https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.14871
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet.</i> 2017;389:2287-2303.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31191-1/fulltext
Brar KK, Nicol NH, Boguniewicz M. Strategies for successful management of severe atopic dermatitis. <i>J Allergy Clin Immunol Pract.</i> 2019;7:1-16.	https://www.sciencedirect.com/science/article/abs/pii/S2213219818306780

<p>Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. <i>J Am Acad Dermatol.</i> 2018;78(3 suppl 1):S53-S62.</p>	<p>https://www.jaad.org/article/S0190-9622(17)32820-7/fulltext</p>
<p>Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. <i>J Allergy Clin Immunol.</i> 2019;143:1-11.</p>	<p>https://www.jacionline.org/article/S0091-6749(18)31572-0/fulltext</p>
<p>Ellis RM, Koch LH, McGuire E, Williams JV.. Potential barriers to adherence in pediatric dermatology. <i>Pediatr Dermatol.</i> 2011;28:242-244.</p>	<p>https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1525-1470.2011.01493.x</p>
<p>Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials. <i>J Am Acad Dermatol.</i> 2018;78:62-69.e1</p>	<p>https://www.jaad.org/article/S0190-9622(17)32457-X/fulltext</p>
<p>Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. <i>J Am Acad Dermatol.</i> 2019;80:913-921.e9.</p>	<p>https://www.jaad.org/article/S0190-9622(18)30129-4/fulltext</p>
<p>Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): Results from two replicate double-blind, randomised controlled phase 3 trials. <i>Lancet.</i> 2021;397(10290):2151-2168.</p>	<p>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00588-2/fulltext</p>
<p>Janeczek M, Moy L, Riopelle A, et al. The potential uses of N-acetylcysteine in dermatology: A review. <i>J Clin Aesthet Dermatol.</i> 2019;12:20-26.</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561714/</p>
<p>Jarnagin K, Chanda S, Coronado D, et al. Crisaborole topical ointment, 2%: A nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. <i>J Drugs Dermatol.</i> 2016;15:390-396.</p>	<p>https://jddonline.com/articles/dermatology/S1545961616P0390X</p>
<p>Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. <i>J Allergy Clin Immunol.</i> 2018;142:1121-1130.e7.</p>	<p>https://www.jacionline.org/article/S0091-6749(18)30698-5/fulltext</p>
<p>Khattari S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. <i>Exp Dermatol.</i> 2017;26:28-35.</p>	<p>https://onlinelibrary.wiley.com/doi/abs/10.1111/exd.13112</p>
<p>Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: A systematic review. <i>JAMA Dermatol.</i> 2017;153:1036-1042.</p>	<p>https://jamanetwork.com/journals/jamadermatology/article-abstract/2643740</p>
<p>Lio PA, Lee M, LeBovidge J, et al. Clinical management of atopic dermatitis: Practical highlights and updates from the atopic dermatitis practice parameter 2012. <i>J Allergy Clin Immunol Pract.</i> 2014;2:361-369.</p>	<p>https://www.sciencedirect.com/science/article/abs/pii/S2213219814000889</p>

Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: Clinical features, pathophysiology, and treatment. <i>Immunol Allergy Clin North Am</i> . 2015;35:161-183.	https://www.sciencedirect.com/science/article/abs/pii/S0889856114001088
Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. <i>Cytokine</i> . 2015;73:311-318.	https://www.sciencedirect.com/science/article/abs/pii/S1043466614006061
Mobasher P, Heydari Seradj M, Raffi J, Juhasz M, Atanaskova Mesinkovska N. Oral small molecules for the treatment of atopic dermatitis: A systematic review. <i>J Dermatolog Treat</i> . 2019;30:550-557.	https://www.tandfonline.com/doi/full/10.1080/09546634.2018.1544412
Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. <i>J Am Acad Dermatol</i> . 2016;75:494-503.e6.	https://www.jaad.org/article/S0190-9622(16)30330-9/fulltext
Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. <i>J Am Acad Dermatol</i> . 2021;85:863-872.	https://www.jaad.org/article/S0190-9622(21)00931-2/fulltext
Pan Y, Xu L, Qiao J, Fang H. A systematic review of ustekinumab in the treatment of atopic dermatitis. <i>J Dermatolog Treat</i> . 2018;29:539-541.	https://www.tandfonline.com/doi/full/10.1080/09546634.2017.1406894
Puya R, Alvarez-López M, Velez A, Casas Asuncion E, Moreno JC. Treatment of severe refractory adult atopic dermatitis with ustekinumab. <i>Int J Dermatol</i> . 2012;51:115-116.	https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-4632.2011.05195.x
Raffin D, Giraudeau B, Samimi M, Machet L, Pourrat X, Maruani A. Corticosteroid phobia among pharmacists regarding atopic dermatitis in children: A national French survey. <i>Acta Derm Venereol</i> . 2016;96:177-180.	https://www.medicaljournals.se/acta/content/abstract/10.2340/0015555-2157
Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. <i>J Eur Acad Dermatol Venereol</i> . 2012;26:1045-1060.	https://onlinelibrary.wiley.com/doi/full/10.1111/j.1468-3083.2012.04635.x
Ruzicka T, Mihara R. Anti-interleukin-31 receptor A antibody for atopic dermatitis. <i>N Engl J Med</i> . 2017;376:826-835.	https://www.nejm.org/doi/10.1056/NEJMoa1606490
Samorano LP, Hanifin JM, Simpson EL, Leshem YA. Inadequate response to ustekinumab in atopic dermatitis - A report of two patients. <i>J Eur Acad Dermatol Venereol</i> . 2016;30:522-523.	https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.12918
Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: A phase IV open-label study (CrisADe CARE 1). <i>Am J Clin Dermatol</i> . 2020;21:275-284.	https://link.springer.com/article/10.1007/s40257-020-00510-6
Shi VY, Nanda S, Lee K, Armstrong AW, Lio PA. Improving patient education with an eczema action	https://jamanetwork.com/journals/jamadermatology/fullarticle/1670411

plan: A randomized controlled trial. <i>JAMA Dermatol.</i> 2013;149:481-483.	
Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. <i>J Am Acad Dermatol.</i> 2014;71:327-349.	https://www.jaad.org/article/S0190-9622(14)01264-X/fulltext
Siegfried EC, Jaworski JC, Eichenfield LF, et al. Developing drugs for treatment of atopic dermatitis in children (≥ 3 months to < 18 years of age): Draft guidance for industry. <i>Pediatr Dermatol.</i> 2018;35:303-322.	https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.13452
Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A randomized clinical trial. <i>JAMA Dermatol.</i> 2020;156:863-873.	https://jamanetwork.com/journals/jamadermatology/fullarticle/2766772
Simpson EL, Imafuku S, Poulin Y, et al. A phase 2 randomized trial of apremilast in patients with atopic dermatitis. <i>J Invest Dermatol.</i> 2019;139:1063-1072.	https://www.jidonline.org/article/S0022-202X(18)32905-1/fulltext
Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: Results from two randomized monotherapy phase III trials. <i>Br J Dermatol.</i> 2020;183:242-255.	https://onlinelibrary.wiley.com/doi/10.1111/bjd.18898
Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet.</i> 2020;396:255-266.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30732-7/fulltext
Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). <i>J Am Acad Dermatol.</i> 2018;78:863-871.e11.	https://www.jaad.org/article/S0190-9622(18)30102-6/fulltext
Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. <i>J Am Acad Dermatol.</i> 2016;74:491-498.	https://www.jaad.org/article/S0190-9622(15)02471-8/fulltext
Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. <i>J Am Acad Dermatol.</i> 2019;80:1013-1021.	https://www.jaad.org/article/S0190-9622(18)33050-0/fulltext
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. <i>N Engl J Med.</i> 2016;375:2335-2348.	https://www.nejm.org/doi/10.1056/NEJMoa1610020
Smith SD, Stephens AM, Werren JC, Fischer GO. Treatment failure in atopic dermatitis as a result of parental health belief. <i>Med J Aust.</i> 2013;199:467-469.	https://pubmed.ncbi.nlm.nih.gov/24099206/

Snyder A, Farhangian M, Feldman SR. A review of patient adherence to topical therapies for treatment of atopic dermatitis. <i>Cutis</i> . 2015;96:397-401.	https://www.mdedge.com/dermatology/article/105176/atopic-dermatitis/review-patient-adherence-topical-therapies-treatment
Thyssen JP, de Bruin-Weller MS, Paller AS, et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. <i>J Eur Acad Dermatol Venereol</i> . 2019;33:1224-1231.	https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.15608
Thaci D, Chambers C, Sidhu M, Dorsch B, Ehlken B, Fuchs S. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: Clinical efficacy and economic impact over 12 months. <i>J Eur Acad Dermatol Venereol</i> . 2010;24:1040-1046.	https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1468-3083.2010.03577.x
Torrelo A, Ortiz J, Alomar A, Ros S, Pedrosa E, Cuervo J. Health-related quality of life, patient satisfaction, and adherence to treatment in patients with moderate or severe atopic dermatitis on maintenance therapy: The CONDA-SAT study. <i>Actas Dermosifiliogr</i> . 2013;104:409-417.	https://www.actasdermo.org/en-linkresolver-health-related-quality-life-patient-satisfaction-S1578219013000954
Treister AD, Lio PA. Long-term off-label dupilumab in pediatric atopic dermatitis: A case series. <i>Pediatr Dermatol</i> . 2019;36:85-88.	https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.13697
Wang D, Beck LA. Immunologic targets in atopic dermatitis and emerging therapies: An update. <i>Am J Clin Dermatol</i> . 2016;17:425-443.	https://link.springer.com/article/10.1007/s40257-016-0205-5
Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. <i>J Eur Acad Dermatol Venereol</i> . 2016;30:729-747.	https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.13599
Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. <i>J Allergy Clin Immunol</i> . 2006;118:226-232.	https://www.jacionline.org/article/S0091-6749(06)00450-7/fulltext

COVID-19 Guidance and Research

Resource	Address
American Academy of Dermatology Association (AAD). Clinical Guidance for COVID-19. Accessed November 8, 2021.	https://www.aad.org/member/practice/coronavirus/clinical-guidance
Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: A randomized clinical trial. <i>JAMA Dermatol</i> . 2021;157(9):1047-1055.	https://jamanetwork.com/journals/jamadermatology/fullarticle/2782803
da Silva RP, Gonçalves JIB, Zanin RF, Schuch FB, de Souza APD. Circulating type I interferon levels and COVID-19 severity: A systematic review and meta-analysis. <i>Front Immunol</i> . 2021;12:657363.	https://www.frontiersin.org/articles/10.3389/fimmu.2021.657363/full

<p>International League of Dermatological Societies (ILDS). Guidance on the Use of Systemic Therapy for Patients with Psoriasis/Atopic Dermatitis During the COVID-19 (Sars-Cov-2, Coronavirus) Pandemic (updated March 2021).</p>	<p>https://ilds.org/covid-19/guidance-psoriasis-atopic-dermatitis/</p>
<p>Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. <i>Autoimmun Rev.</i> 2020;19:102567.</p>	<p>https://www.sciencedirect.com/science/article/pii/S1568997220301294</p>
<p>Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. <i>Arthritis Rheumatol.</i> 2021;73:e1-e12.</p>	<p>https://onlinelibrary.wiley.com/doi/10.1002/art.41596</p>
<p>National Psoriasis Foundation. COVID-19 Task Force Guidance Statements. Accessed November 8, 2021.</p>	<p>https://www.psoriasis.org/covid-19-task-force-guidance-statements/</p>
<p>Thyssen JP, Vestergaard C, Barbarot S, et al. European Task Force on Atopic Dermatitis: Position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. <i>J Eur Acad Dermatol Venereol.</i> 2021;35:e308-e311.</p>	<p>https://onlinelibrary.wiley.com/doi/10.1111/jdv.17167</p>